A clinical study evaluating the efficacy and safety of an immunotherapy with a mixture of D. pteronyssinus, D. farinae and B. tropicalis three mites (ALXOID) in patients with allergic rhinoconjunctivitis, with or without asthma, due to sensitization to these mites
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Phleum pratense cluster allergy immunotherapy ROXALL Medizin GmbH (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
Most Recent Events
- 16 Dec 2022 New trial record